Press Room

ISPE UK Annual Conference 2023

Start
Thursday, November 30, 2023 - 15:45
Location: Coventry, United Kingdom

Join Hovione and GEA presentation at ISPE UK 2023

Title: “Delivering the Benefits of Continuous Tableting to the Pharmaceutical Industry”
 

Filipe Gaspar - VP Technology Intensification will be co-hosting a session at the event with Phillip Gabb from GEA focusing on the opportunities and challenges that Continuous Tableting presents to the pharmaceutical industry. In this session they will describe how both companies are working together and combining GEA´s engineering expertise with Hovione´s development and manufacturing experience to accelerate the adoption of this emerging technology.

 

This year's event, which will follow the established format of a full day of lectures, running alongside a bustling exhibition with over 45 manufacturers, suppliers and pharmaceutical industry decision makers during the day is followed by the ISPE Annual Awards Dinner in the evening. ISPE is a volunteer led organisation and the awards dinner is a chance to say 'thank you' to the volunteer members who enable events and training sessions throughout the year. 
 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026